ReNeuron Group

About ReNeuron Group

ReNeuron is a leading clinical-stage stem cell company focused on developing innovative stem cell therapies to address significant unmet or poorly met medical needs. The company operates in the biotechnology sector, primarily targeting conditions that lack effective treatment options. ReNeuron's business model revolves around conducting well-designed clinical trials to gain clinical validation for its cell therapy programs in regulated markets. The company generates revenue through partnerships, licensing agreements, and potential future product sales. ReNeuron also advances its exosome platform, which uses nano-sized particles to deliver third-party drugs, enhancing the therapeutic potential of its treatments. The company serves patients, healthcare providers, and pharmaceutical partners, aiming to bring groundbreaking therapies to market. ReNeuron is incorporated in the UK, with offices in both the UK and the US, and its shares are traded on the London Stock Exchange.